<DOC>
	<DOCNO>NCT01441947</DOCNO>
	<brief_summary>The study drug cabozantinib work inhibit several different protein believe involved breast cancer tumor growth , ability spread , ability form new blood vessel . This drug use research study information research study suggest drug may help prevent cancer growth . The single agent portion study close accrual . This research study examine efficacy cabozantinib combination fulvestrant treatment hormone-receptor-positive breast cancer spread bone .</brief_summary>
	<brief_title>Cabozantinib Women With Metastatic Hormone-Receptor-Positive Breast Cancer</brief_title>
	<detailed_description>Cabozantinib take orally day cycle 28 day ( 4 week ) . Fulvestrant give intramuscularly day 1 15 cycle 1 day 1 subsequent cycle . On Day 1 cycle subject follow test procedure : - Performance status - Physical exam - Vital sign - Routine blood sample - Blood urine sample look bone marker ( Cycle 1 6 ) Subjects also follow additional test procedure : - Tumor assessment CT scan bone scan Cycle 3 , every 12 week - Blood urine pregnancy test ( applicable ) Day 1 Cycles 1 , 2 , 4 , every 12 week - Urine sample blood test thyroid function ( Cycle 1 , 3 , 5 , every 6 week ) - Blood test breast cancer tumor marker ( Cycle 1 4 , every 6 week ) - Pain questionnaire painkiller medication diary 7-day interval Week 3 , Week 6 , every 6 week thereafter .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<mesh_term>Fulvestrant</mesh_term>
	<criteria>Clear evidence metastasis bone isotope bone scan Histologically cytologically confirm metastatic Estrogenreceptorpositive ( ER+ ) and/or Progesteronereceptorpositive ( PR+ ) HER2 negative breast cancer Received least one prior line hormonal chemotherapy metastatic disease must post menopausal Recovered toxicity relate prior treatment , except alopecia , lymphopenia , nonclinically significant Adverse Events ( AEs ) Life expectancy &gt; 3 month Adequate organ marrow function Sexually active fertile subject partner must agree use medically accept method contraception Able lie flat 45 minute image study Able swallow capsule tablet Pregnant breastfeeding Has experience clinicallysignificant hematemesis hemoptysis &gt; 0.5 teaspoon red blood , sign indicative pulmonary hemorrhage within 3 month first dose study treatment Untreated , symptomatic uncontrolled brain metastasis require current treatment include steroid anticonvulsant 1 prior line chemotherapy treatment metastatic breast cancer prior treatment fulvestrant Requires concomitant treatment , therapeutic dos , anticoagulant warfarin coumadinrelated agent , thrombin FXa inhibitor , antiplatelet agent ( eg , clopidogrel ) Uncontrolled significant intercurrent illness Gastrointestinal disorder , particularly associate high risk perforation fistula formation Active infection require systemic treatment Serious nonhealing wound/ulcer/bone fracture History organ transplant Concurrent uncompensated hypothyroidism thyroid dysfunction Previouslyidentified allergy hypersensitivity component study treatment formulation Diagnosis another malignancy , require systemic treatment , within last 2 year , unless nonmelanoma skin cancer , insitu carcinoma cervix , superficial bladder cancer</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>ER+</keyword>
	<keyword>PR+</keyword>
	<keyword>HER2-</keyword>
	<keyword>metastatic</keyword>
</DOC>